Business
Bruker develops scientific instruments, diagnostics and analytical systems.
Bruker's modest growth produced only break-even profit and thin free cash flow as acquisition and restructuring burdens weighed on otherwise attractive scientific markets.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 2.1%OK
- Profitability — The company moved from net income of $113.1M to a net loss of $8.6MWatch
- Cash flow — Free cash flow declined 68.2% to $43.3M from $136MWatch
- Margins — Operating margin contracted 554 bps to 1.98%Watch
- Accounting — Growth with acquisition and restructuring dragNote
- Insiders — 0 purchases and 11 salesWatch
Where the revenue comes from
Fiscal 2025, as BRUKER CORP reports it. History and quarterly detail are in the app.
- Bsi Calid$1.2B
- Bsi Nano$1.1B
- Bsi Biospin$878.8M
- Energy And Supercon Technologies$270.9M
Leadership changes
From BRUKER CORP's own filings, the day they're filed.
- Thierry L. Bernard · director · appointmenteff. 2026-04-01
- Jack Phillips · director · departureeff. 2026-02-19
- Jack J. Phillips · director · appointmenteff. 2026-01-01
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BRUKER CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.